DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Consensus Target Price from Brokerages

Posted by on May 23rd, 2026

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $12.3333.

Several equities research analysts have recently commented on DMAC shares. Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th.

View Our Latest Research Report on DMAC

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after purchasing an additional 16,446 shares in the last quarter. Renaissance Technologies LLC bought a new stake in DiaMedica Therapeutics in the 1st quarter worth about $356,000. Sei Investments Co. grew its position in DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after purchasing an additional 55,660 shares in the last quarter. World Investment Advisors grew its position in DiaMedica Therapeutics by 7.7% in the 4th quarter. World Investment Advisors now owns 36,975 shares of the company’s stock worth $294,000 after purchasing an additional 2,650 shares in the last quarter. Finally, Invesco Ltd. grew its position in DiaMedica Therapeutics by 29.9% in the 4th quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock worth $148,000 after purchasing an additional 4,293 shares in the last quarter. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $5.91 on Monday. The firm has a 50-day moving average of $6.48 and a 200-day moving average of $7.50. The company has a market cap of $318.43 million, a PE ratio of -8.32 and a beta of 0.99. DiaMedica Therapeutics has a one year low of $3.47 and a one year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, equities research analysts expect that DiaMedica Therapeutics will post -0.86 earnings per share for the current fiscal year.

About DiaMedica Therapeutics

(Get Free Report)

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

Featured Stories

Analyst Recommendations for DiaMedica Therapeutics (NASDAQ:DMAC)

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.